Начало・Списък с акции・MannKind Corp

MannKind Corp

Отворен

СекторЗдравеопазване

4.11 3.79

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.89

Максимум

4.09

Ключови измерители
By Trading Economics
Приходи	-671K -17M
Продажби	-22M 90M
P/E Средно за сектора	140.5 68.51
EPS	-0.02
Марж на печалбата	-18.431
Служители	591
EBITDA	5M 2.5M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+120.96% upside

Дивиденти
By Acuity
Следващи печалби	5.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	306M 1.2B
Предишно отваряне	0.32
Предишно затваряне	4.11

Настроения в новините

By Acuity

59%

41%

288 / 340 Класиране в Healthcare

MannKind Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

4.08.2026 г., 23:26 ч. UTC

MannKind Corp shares are lower in after-market hours, with no specific news identified to explain the price movement. Trading has remained within a narrow range.

3.08.2026 г., 22:51 ч. UTC

MannKind Corp shares are higher in after-market trading, reflecting momentum since Monday's close amid falling Brent crude oil prices and positive market sentiment.

31.07.2026 г., 23:56 ч. UTC

MannKind Corp shares traded lower in after-market hours, retreating from earlier gains. The stock remains near the lower end of its one-month range.

30.07.2026 г., 18:41 ч. UTC

Event

News

Wells Fargo raised MannKind's price target to $14.00, contributing to positive momentum. The company also reported favorable Phase 1b study results today.

29.07.2026 г., 19:47 ч. UTC

News

Event

MannKind Corp reported positive results from its Phase 1b INFLO-1 study, but shares are trading lower amid broader market uncertainty ahead of the Fed's decision.

28.07.2026 г., 21:01 ч. UTC

News

MannKind Corp will report its second quarter 2026 financial results on August 5, 2026. Shares are trading higher in after-market hours.

27.07.2026 г., 22:06 ч. UTC

MannKind Corp shares are higher in after-market trading, despite earlier declines. No specific news was identified to explain the price movement.

24.07.2026 г., 21:01 ч. UTC

Event

MannKind Corp shares are rising in after-market trading following FDA approval of Furoscix ReadyFlow™ for treating edema in heart failure and chronic kidney disease.

23.07.2026 г., 10:36 ч. UTC

MannKind Corp shares are higher in pre-market trading, continuing an upward trend since Wednesday, despite declines in the broader tech sector.

22.07.2026 г., 21:01 ч. UTC

MannKind Corp shares are higher in after-market trading, reflecting a gain since Wednesday's close, despite remaining below the 20-day moving average.

21.07.2026 г., 22:11 ч. UTC

MannKind Corp shares rose in after-market trading, reflecting a broader rebound in technology stocks and strong interest in semiconductor and AI investments.

Сравнение с други в отрасъла

Ценова промяна

MannKind Corp Прогноза

Ценова цел

By TipRanks

120.96% нагоре

12-месечна прогноза

Среден 8.75 USD 120.96%

Висок 14 USD

Нисък 4.75 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за MannKind Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

6 ratings

Купи

Задържане

Продай

Според 6 анализатори, дали борсови рейтинги на MannKind Corp през последните 3 месеца.

Настроение

By Acuity

288 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.